Rezolute, Inc. (RZLT)
| Market Cap | 421.19M -54.0% |
| Revenue (ttm) | n/a |
| Net Income | -77.92M |
| EPS | -0.75 |
| Shares Out | 104.90M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,889,896 |
| Open | 3.600 |
| Previous Close | 3.580 |
| Day's Range | 3.460 - 4.035 |
| 52-Week Range | 1.070 - 11.165 |
| Beta | 0.62 |
| Analysts | Strong Buy |
| Price Target | 10.80 (+168.99%) |
| Earnings Date | Nov 5, 2026 |
About RZLT
Rezolute, Inc., a late-stage rare disease company, focuses developing therapies that treat refractory and debilitating hypoglycemia associated with various forms of hyperinsulinism (HI) in the United States. Its lead clinical asset is ersodetug, an intravenously administered human monoclonal antibody which is in Phase 3 clinical trial to treat tumor HI indication, as well as congenital HI. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was founded in 2010 and is headquar... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 11 analysts, the average rating for RZLT stock is "Strong Buy." The 12-month stock price target is $10.8, which is an increase of 168.99% from the latest price.
News
Rezolute price target raised to $10 from $6 at Wedbush
Wedbush raised the firm’s price target on Rezolute (RZLT) to $10 from $6 and keeps an Outperform rating on the shares after last Friday’s announcement of positive preliminary data from…
Rezolute price target raised to $15 from $12 at Lake Street
Lake Street analyst Daniel Brims raised the firm’s price target on Rezolute (RZLT) to $15 from $12 and keeps a Buy rating on the shares after the company announced “positive”…
Rezolute Slides: Corporate presentation
Rezolute has posted slides in relation to its latest quarterly earnings report, which was published on November 13, 2026.
Rezolute prices 22.04M shares of common stock at $3.87
Rezolute (RZLT) announced the pricing of an underwritten offering of 22,040,976 shares of its common stock at an offering price of $3.87 per share, and to certain investors in lieu…
Rezolute reports results from open-label Phase 3 upLIFT study
Rezolute (RZLT) announced positive results from the ongoing open-label Phase 3 upLIFT study of ersodetug in tumor HI, in which the primary efficacy endpoint has been achieved, based on preliminary…
Rezolute Announces Pricing of Approximately $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
Transaction led by Frazier Life Sciences with participation from new and existing funds REDWOOD CITY, Calif., Nov. 13, 2026 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (Rezolute or the Company),...
Rezolute Announces Positive Results from the Phase 3 upLIFT Study in Tumor Hyperinsulinism
Primary efficacy endpoint achieved based on preliminary results from a November 5th data evaluation
Rezolute Transcript: Guggenheim 3rd Annual Healthcare Innovation Conference
Phase III is complete for congenital disease, with tumor top-line results expected soon. Plans target a congenital BLA next year, while market estimates total ~6,000 patients and a $5B+ opportunity.
Rezolute price target raised to $10 from $7 at Craig-Hallum
Craig-Hallum analyst Albert Lowe raised the firm’s price target on Rezolute (RZLT) to $10 from $7 and keeps a Buy rating on the shares. The firm cites increased probabilities of…
Rezolute reports Q1 EPS (18c), consensus (19c)
The company said, “Cash, cash equivalents and investments in marketable securities were $90.0 million as of September 30, 2026, compared with $107.8 million as of June 30, 2026.” Published first…
Rezolute files $400M mixed securities shelf
16:56 EST Rezolute (RZLT) files $400M mixed securities shelf
Rezolute Reports First Quarter Fiscal 2027 Financial Results and Provides Business Update
REDWOOD CITY, Calif., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (Rezolute or the Company), a late-stage ultra-rare, metabolic disease company focused on treating refractory hypog...
Rezolute Earnings release: Q1 2027
Rezolute released its Q1 2027 earnings on November 5, 2026, summarizing the period's financial results.
Rezolute Quarterly report: Q1 2027
Rezolute has published its Q1 2027 quarterly earnings report on November 5, 2026.
Rezolute Registration statement: Registration filing
Rezolute filed a registration statement on November 5, 2026, providing details about a securities offering with the SEC.
Rezolute to Participate in Upcoming Investor Conferences
REDWOOD CITY, Calif., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (Rezolute or Company), a late-stage ultra-rare, metabolic disease company focused on treating refractory hypoglyce...
Rezolute Proxy statement: Proxy filing
Rezolute filed a proxy statement on October 21, 2026, providing details for shareholder voting and corporate governance matters.
Rezolute Slides: Corporate presentation
Rezolute has posted slides in relation to its latest quarterly earnings report, which was published on October 21, 2026.
Rezolute completes enrollment in upLIFT study of ersodetug
Rezolute (RZLT) announced that the open-label Phase 3 study of ersodetug in tumor HI, or upLIFT, is now fully enrolled and topline data are expected mid-December. The company plans to…
Rezolute Announces Completion of Enrollment in Phase 3 upLIFT Study of Ersodetug in Tumor Hyperinsulinism
Topline results expected mid-December 2026 REDWOOD CITY, Calif., Oct. 14, 2026 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (Rezolute or Company), a late-stage ultra-rare disease company focused ...
Rezolute Proxy statement: Proxy filing
Rezolute filed a proxy statement on October 7, 2026, providing details for shareholder voting and corporate governance matters.
Rezolute price target raised to $12 from $9 at Lake Street
Lake Street analyst Daniel Brims raised the firm’s price target on Rezolute (RZLT) to $12 from $9 and keeps a Buy rating on the shares after the company announced feedback…
Rezolute price target raised to $15 from $11 at Citizens
Citizens raised the firm’s price target on Rezolute (RZLT) to $15 from $11 and keeps an Outperform rating on the shares. Rezolute’s FDA feedback is a meaningful positive, with the…
Rezolute upgraded to Overweight from Neutral at Cantor Fitzgerald
Cantor Fitzgerald upgraded Rezolute (RZLT) to Overweight from Neutral. The firm is positive on the FDA recommendation to hold a pre-BLA meeting for ersodetug in congenital hyperinsulinism as announced...
Rezolute announces FDA recommendation to hold pre-BLA meeting for ersodetug
Rezolute (RZLT) announced that following a preliminary review of detailed data from the Phase 3 sunRIZE study of ersodetug for the treatment of hypoglycemia due to congenital HI, the FDA…